New hope for kids with lingering leukemia: targeted drug aims to wipe out hidden cancer cells
NCT ID NCT03913559
First seen Feb 05, 2026 · Last updated May 21, 2026 · Updated 10 times
Summary
This study tested a drug called inotuzumab ozogamicin (Besponsa) in children and young adults with a type of leukemia (B-ALL) that still had small amounts of cancer cells after standard treatment. The drug works like a smart bomb, targeting a protein (CD22) found on most leukemia cells to deliver a powerful toxin. The goal was to see if it could clear those leftover cells and improve outcomes, but the study was stopped early after enrolling only 5 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rady Children's Hospital San Diego
San Diego, California, 92123, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Conditions
Explore the condition pages connected to this study.